Exploring membrane proteins of Leishmania major to design a new multi-epitope vaccine using immunoinformatics approach

Rabienia, Mahsa; Roudbari, Zahra; Ghanbariasad, Ali; Abdollahi, Abbas; Mohammadi, Elyas; Mortazavidehkordi, Nahid; Farjadfar, Akbar

doi:10.1016/j.ejps.2020.105423

Cited by 20 publications

(12 citation statements)

References 65 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In contrast to our study, only preliminary in-silico analyses were done for the 45.9 kDa candidate without secondary structure prediction, protein disulfide engineering, molecular docking and evaluation of immunological profile (Hashemzadeh et al 2020 ). Another study by Rabienia et al ( 2020 ) utilized B- and T cell as well as IFN-γ inducing epitopes of L. major KMP-11 and HASPB to engineer a multi-epitope vaccine candidate (27.17 kDa), adjoined by GDGDG linker and profilin as adjuvant. Docking results demonstrated that profilin adequately binds well to TLR11 and the vaccine/receptor interaction is stable (Rabienia et al 2020 ).…”

Section: Discussionmentioning

confidence: 99%

Engineering a multi-epitope vaccine candidate against Leishmania infantum using comprehensive Immunoinformatics methods

et al. 2021

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 99%

Engineering a multi-epitope vaccine candidate against Leishmania infantum using comprehensive Immunoinformatics methods

et al. 2021

View full text Add to dashboard Cite

“…So, it is imperative that the sector finds ways of reducing the expenditures and time of drug discovery and vaccine development (such as drug repositioning (70,71)) and escalating efficiency. Bioinformatics is one of the tools the industry has recently engaged to aid in the drug discovery (72)(73)(74) and vaccine development process (75)(76)(77)(78)(79) as well as to cut costs and the timelines. Accordingly, in this study we aimed to design and analyze the probability of producing a universal and cross-protective avian influenza vaccine through bioinformatic tools to diminish unnecessary laboratory costs.…”

Section: Discussionmentioning

confidence: 99%

Design and Computational Analysis of a Chimeric Avian Influenza Antigen: A Yeast-displayed, Universal and Cross-protective Vaccine Candidate

Mohammadi

Pirkhezranian²,

Dashty

et al. 2021

Preprint

Self Cite

View full text Add to dashboard Cite

Background: A cross-protective avian influenza vaccine candidate can be designed by using a preserved antigen against mutation in various subtypes of influenza. M2e peptide sequence has remained remarkably unchanged in influenza type A isolated since 1918. Methods: A consensus sequence of M2e peptide was obtained from 31 sequences of H5N8, H5N1, H9N2 and H7N9 subtypes of avian influenza virus isolated from 7 avian species in 5 Asian countries. A partial sequence of flagellin was considered as an adjuvant. Subsequently, two chimeric antigens were designed to be virtually cloned and expressed using PYD1 vector and EBY100 yeast strain. The stability and conformational features of these two antigens were assessed through molecular dynamic (MD) simulations. The detectability of vaccine candidates by a specific monoclonal antibody (MAb148) were estimated through docking studies. Results: In spite of significant compactness and stability of the first candidate in comparison with the second design, it was less detectable by MAb148. Contrary to the first chimeric antigen, Van der Waals, electrostatic and binding energies of the interaction of the second antigen with MAb148 were significantly closer to the positive control. It is shown that epitopes of the second chimeric antigen could be correctly located in the specific pocket of CDR region of MAb148. Conclusion: The second chimeric antigen could be considered as a yeast-displayed avian influenza vaccine candidate due to the capability of provoking humoral immunity and innate immune system by M2e and flagellin respectively.

show abstract

“…The ID of KMP11 and HASPB was AAR84616.1 and CAB39972.1, respectively. Then, with the help of immunoinformatics software such as T-cell epitope prediction, B-cell epitope prediction, docking studies and molecular dynamics simulation, the epitopes of KMP11 and HASPB proteins were selected in silico space (15). Also, using GDGDG linker, nal multi-epitope vaccine was designed ( Figure. The cells were supplemented with 10% foetal bovine serum (FBS) (Gibco, USA), penicillin (100 units/ml)/streptomycin (100 mg/ml) (Invitrogen, Carlsbad, CA, USA), nally the cells were incubated in a humidi ed atmosphere with 5% CO2 at 37°C.…”

Section: Design Of Multi-epitope Lentiviral Vaccinementioning

confidence: 99%

Immunogenicity Evaluation of a Novel Lentiviral Vaccine Expressing Multi- Epitope Against of Leishmania Major in BALB/c Mice

Rabienia

Roudbari

Ghanbariasad

et al. 2020

Preprint

Self Cite

View full text Add to dashboard Cite

Background: Nowadays, the prevention of parasitic diseases including leishmaniasis is one of the health concerns in the world, and cutaneous leishmaniasis is the most common type of these diseases. So far, no drug or vaccine has been approved for definitive treatment of this disease.Methods: In this study, the recombinant lentiviral vaccine containing a new multi-epitope of KMP11 and HASPB of the Leishmania major (L. major) was synthesized that had previously been designed in-silico. The designed multi-epitope was subcloned into the pCDH513 lentiviral vector, and the recombinant lentiviral multi-epitope vaccine (rLV-multi-epitope) was synthesized in the HEK293T cell by the packaging vectors. Also, the Western Blotting method was used to confirm the gene expression. Then, the rLV-multi-epitope vaccine was injected twice, along with two control groups, PBS, and rLV-empty to immunize the BALB /c mice. Twenty-one days after the second injection, the splenocytes of the mice were isolated and stimulated with the Leishmania lysate.Results: The results of the enzyme-linked immunoassay (ELISA) test not only showed the titer of IFN-γ and IL-4 was increased in the immunized group compared to the controls, but also indicated that the ratio of IFN-γ to IL-4 cytokines in the main group was increased significantly. As a result, the Th1 response was generated in the main group. Moreover, the humoral immune response was assessed and the results showed that the ratio of IgG2a to IgG1 antibody in the sera of the immunized mice was increased compared to the control groups. Also, the ratio of IgG2a to IgG1 was increased in the main group. Therefore, the humoral immune response was increased, which can also have a positive effect on increasing the Th1 response.Conclusions: Our results showed that immunization by the new rLV-multi-epitope vaccine could stimulate the immune system towards the Th1 through increasing the IFN-γ production.

show abstract

Exploring membrane proteins of Leishmania major to design a new multi-epitope vaccine using immunoinformatics approach

Cited by 20 publications

References 65 publications

Engineering a multi-epitope vaccine candidate against Leishmania infantum using comprehensive Immunoinformatics methods

Engineering a multi-epitope vaccine candidate against Leishmania infantum using comprehensive Immunoinformatics methods

Design and Computational Analysis of a Chimeric Avian Influenza Antigen: A Yeast-displayed, Universal and Cross-protective Vaccine Candidate

Immunogenicity Evaluation of a Novel Lentiviral Vaccine Expressing Multi- Epitope Against of Leishmania Major in BALB/c Mice

Contact Info

Product

Resources

About